Dimerix Ltd - Asset Resilience Ratio
Dimerix Ltd (DXB) has an Asset Resilience Ratio of 74.89% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Dimerix Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Dimerix Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Dimerix Ltd.
Liquid Assets Composition Over Time
This chart breaks down Dimerix Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read DXB total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$68.28 Million | 74.89% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$68.28 Million | 74.89% |
Asset Resilience Insights
- Very High Liquidity: Dimerix Ltd maintains exceptional liquid asset reserves at 74.89% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Dimerix Ltd Industry Peers by Asset Resilience Ratio
Compare Dimerix Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Dimerix Ltd (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Dimerix Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 74.89% | AU$68.28 Million ≈ $48.32 Million |
AU$91.18 Million ≈ $64.51 Million |
+5.87pp |
| 2024-06-30 | 69.02% | AU$22.14 Million ≈ $15.67 Million |
AU$32.08 Million ≈ $22.70 Million |
+24.02pp |
| 2023-06-30 | 45.01% | AU$7.99 Million ≈ $5.65 Million |
AU$17.76 Million ≈ $12.56 Million |
-13.37pp |
| 2022-06-30 | 58.37% | AU$9.63 Million ≈ $6.81 Million |
AU$16.50 Million ≈ $11.67 Million |
+2.64pp |
| 2021-06-30 | 55.73% | AU$5.25 Million ≈ $3.71 Million |
AU$9.42 Million ≈ $6.67 Million |
-19.21pp |
| 2020-06-30 | 74.94% | AU$7.79 Million ≈ $5.51 Million |
AU$10.39 Million ≈ $7.35 Million |
+2.82pp |
| 2019-06-30 | 72.12% | AU$3.56 Million ≈ $2.52 Million |
AU$4.94 Million ≈ $3.50 Million |
-14.38pp |
| 2018-06-30 | 86.50% | AU$6.28 Million ≈ $4.45 Million |
AU$7.26 Million ≈ $5.14 Million |
+8.35pp |
| 2017-06-30 | 78.16% | AU$2.24 Million ≈ $1.59 Million |
AU$2.87 Million ≈ $2.03 Million |
+44.28pp |
| 2013-06-30 | 33.88% | AU$594.05K ≈ $420.33K |
AU$1.75 Million ≈ $1.24 Million |
-50.95pp |
| 2012-06-30 | 84.83% | AU$1.03 Million ≈ $728.83K |
AU$1.21 Million ≈ $859.19K |
+58.22pp |
| 2011-06-30 | 26.60% | AU$424.00K ≈ $300.01K |
AU$1.59 Million ≈ $1.13 Million |
+10.73pp |
| 2002-06-30 | 15.87% | AU$300.00K ≈ $212.27K |
AU$1.89 Million ≈ $1.34 Million |
-- |
About Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is… Read more